The Diagnostic Contribution of (18)F-FDG PET/CT Scan in Cancer of Unknown Primary

Serdar Savaş Gül

doi:10.7197/223.vi.412273

EN TR

The Diagnostic Contribution of (18)F-FDG PET/CT Scan in Cancer of Unknown Primary

Abstract

OBJECTIVE: The aim of the present study was to evaluate the clinically diagnostic contribution of ¹⁸F-fluorodeoxyglucose positron emission tomography combined with computed tomography(¹⁸F-FDG PET/CT) in patients with cancer of unknown primary (CUP).

METHODS: The retrospective investigation, cross-sectional analysis of 124 ¹⁸F-FDG PET/CT scans of patients with CUP between June 2014 and July 2015 was performed. The increased ¹⁸F-FDG uptake focus were assessed in correlation with histopathology. The diagnostic accuracy, sensitivity, specificity, positive predictive value and negative predictive values were assessed for ¹⁸F-FDG PET/CT.

RESULTS: The ¹⁸F-FDG PET/CT successfully detected primary tumor in 56 patients with high ¹⁸F-FDG uptake involvement (true positive, 45.2%). 58 patients whose final histopathology and clinically without evidence of a primary tumor (true negative, 46.8%). 8 patients whose final histopathologicallyand clinically without evidence of a primary tumor but high ¹⁸F-FDG uptake involvement (false positive, 6.4%). The ¹⁸F-FDG PET/CT scan results were negative for primary site localization in only 2 patients with no ¹⁸F-FDG uptake involvement (false negative, 1.6%). Generally, the diagnostic accuracy was found to be 91.9%, sensitivity 96.5%, specificity 87.8%, positive predictive value 87.5%, negative predictive value 96.6%, positive likelihood ratio 7.9% and negative likelihood ratio 0.04%.

CONCLUSION: It can be said that ¹⁸F-FDG PET/CT may be useful in the diagnosis of patients with CUP.

Keywords

cancer of unknown primary,(18)F-FDG,PET/CT,sensitivity,specificity

Primeri Bilinmeyen Kanserde F(18)-FDG PET/BT Tetkikinin Tanıya Katkısı

Öz

GİRİŞ: Bu çalışmanın amacı, primeri bilinmeyen kanser (PBK) hastalarında 18F-florodeoksiglukoz pozitron emisyon tomografisi/bilgisayarlı tomografinin (F18-FDG PET/BT) klinik olarak tanıya katkısını değerlendirmektir.

YÖNTEM: Retrospektif, kesitsel analiz çalışmasında Haziran 2014-Temmuz 2015 tarihleri arasında 124 PBK hastalarının F18-FDG PET/BT incelemesi yapıldı. Artmış 18F-FDG tutulum odağının histopatoloji ile korelasyonu değerlendirildi. F18-FDG PET/BT için tanısal doğruluk, duyarlılık, özgüllük, pozitif öngörü değeri ve negatif öngörü değerleri hesaplandı.

BULGULAR: F18-FDG PET/BT, yüksek F18-FDG tutulumu olan 56 hastada primer tümör odağını başarıyla saptadı (gerçek pozitif, % 45.2). 58 hastada histopatolojik ve klinik olarak primer tümör bulunamadı (gerçek negatif, % 46.8). 8 hastada yüksek F18-FDG uptake tutulumu olmasına karşın histopatolojik ve klinik olarak primer tümör kanıtı yoktu (yanlış pozitif, % 6.4). Sadece 2 hastada negatif F18-FDG PET/BT tarama sonuç bulunmasına karşın primer tümör histopatolojik olarak saptandı (yanlış negatif, % 1.6) primer yerleşim lokalizasyonu için negatif idi. Genel olarak tanısal doğruluk % 91.9, duyarlılık % 96.5, özgüllük % 87.8, pozitif öngörü değeri % 87.5, negatif öngörü değeri % 96.6, pozitif olabilirlik oranı % 7.9 ve negatif olabilirlik oranı % 0.04 olarak bulundu.

SONUÇ: PBK hastalarının tanısında F18-FDG PET/BT’nin yararlı olabileceği düşünülebilir.

Anahtar Kelimeler

primeri bilinmeyen kanser,F18-FDG PET/BT,duyarlılık,özgüllük

Kaynakça

Fizazi K, Greco FA, Pavlidis N. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi64-68.
Elboga U, Kervancioğlu S, Sahin E, Basibuyuk M, Celen YZ, Aktolun C. Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary. Int J Clin Exp Pathol 2014;7(12):8941-6.
Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009;69:271-8.
Klein CA. Parallel progression of primary tumors and metastases. Nat Rev Cancer 2009;9:302-12.
Kwee TC, Basu S, Alavi A. PET and PET/CT for unknown primary tumors. Methods Mol Biol 2011;727:317-33.
Hasbek Z, Doğan ÖT, Sarı İ, Yücel B, Şeker MM, Turgut B, Berk S, Siliğ Y. The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. Mol Imaging Radionucl Ther 2016;25(3):107-13.
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009;19(3):731-44.
Bochtler T, Löffler H, Kramer A. Diagnosis and management of metastatic neoplasms with unknown primary. Semin Diagn Pathol 2017. pii: S0740-2570(17)30147-8.

Riaz S, Nawaz MK, Faruqui ZS, Kazmi SA, Loya A, Bashir H. Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in the Evaluation of Carcinoma of Unknown Primary. Mol Imaging Radionucl Ther 2016;25(1):11-8.
Talavera-Rubio MP, Garcia-Vicente AM, Palomar-Munoz AM, Pilkington-Woll JP, Poblete-Garcia VM, Soriano-Castrejon A. Usefulness of (18) F-fluorodeoxyglucose-positron emission tomography computerized tomography in the identification of the primary tumor in patients with cancer of unknown origin. Med Clin (Barc) 2013;140:14-9.
Burglin SA, Hess S, Hoilund-Carlsen PF, Gerke O. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96(16):e6713.
Börksüz MF, Erselcan T, Hasbek Z, Yücel B, Turgut B. Morphologic and Metabolic Comparison of Treatment Responsiveness with 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography According to Lung Cancer Type. Mol Imaging Radionucl Ther 2016;25(2):63-9.
Hasbek Z, Yucel B, Salk I, Turgut B, Erselcan T, Babacan NA, Kacan T. Potential impact of atelectasis and primary tumor glycolysis on F-18 FDG PET/CT on survival in lung cancer patients. Asian Pac J Cancer Prev 2014;15(9):4085-9.
Santhanam P, Chandramahanti S, Kroiss A, Yu R, Ruszniewski P, Kumar R, et al. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? Eur J Nucl Med Mol Imaging 2015;42(7):1144-55.
Özman Ö, Arslan N. The Role of PET/CT in Head and Neck Cancer. Turkiye Klinikleri J E.N.T.-Special Topics 2010;3(4):72-81.
Su YY, Chen SS, Hsieh CH, Liao CT, Lin CY, Kang CJ, et al. Defining risk groups of patients with cancer of unknown primary site and cervical nodal metastases by F-18 fluorodeoxyglucose positron emission tomography and computed tomography imaging. Kaohsiung J Med Sci 2016;32(8):407-13.
İnan İE, Kılıç C, Tunçel Ü. The correlation of positron emission tomography-computed tomography assessment with histopathological results in the diagnosis of head and neck cancer of unknown primary. Kulak Burun Bogaz Ihtis Derg 2012;22(6):319-23.
Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, et al. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol 2009;45:218-24.
Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, Freudenberg L, Kuehl H, et al. Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography. Acta Radiol 2007;48:1101-8.
Wang G, Wu Y, Zhang W, Li J, Wu P, Xie C. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary. J Med Imaging Radiat Oncol 2013;57:65-71.
Algin E, Ozet A, Gumusay O, Cetin B, Akdemir UO, Benekli M, et al. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin. Ann Nucl Med 2014;28(9):891-6.
Ouyang L, Shi ZY, Lin ZG. 18F-FDG PET-CT makes a significant contribution to diagnosis of malignancy in patients with cervical lymphadenopathy: a study using optimal scale regression tests. Chin Med J (Engl) 2013;126:659-67.
Chorost MI, Lee MC, Yeoh CB, Molina M, Ghosh BC. Unknown primary. J Surg Oncol 2004;87(4):191-203.
Regelink G, Brouwer J, de Bree R. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 2002;29(8):1024-30.
Stokkel MP, Bongers V, Hordijk GJ, van Rijk PP. FDG positron emission tomography in head and neck cancer: pitfall or pathology? Clin Nucl Med. 1999;24:950-4.
Çakır T, Atasever T. F-18 Flourodeoxy Glucose Positron Emission Tomography/ Computed Tomography Imaging in Infection and Inflammation. Nucl Med Semin 2016;2:79-89.
Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, Freudenberg L, Kuehl H, et al. Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography. Acta Radiol 2007;48:1101-8.
Gutzeit A, Antoch G, Kühl H, Egelhof T, Fischer M, Hauth E, et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 2005;234:227-34.
Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, et al. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev 2008;9:683-6.
Kole AC, Nieweg OE, Pruim J. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-6.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Serdar Savaş Gül ^*
0000-0003-4822-2588
Türkiye

Yayımlanma Tarihi

30 Eylül 2018

Gönderilme Tarihi

3 Nisan 2018

Kabul Tarihi

31 Temmuz 2018

Yayımlandığı Sayı

Yıl 2018 Cilt: 40 Sayı: 3

DOI

https://doi.org/10.7197/223.vi.412273

IZ

https://izlik.org/JA24RB47MM

Kaynak Göster

RIS / Bibtex

AMA

1.Gül SS. The Diagnostic Contribution of (18)F-FDG PET/CT Scan in Cancer of Unknown Primary. CMJ. 2018;40(3):238-245. doi:10.7197/223.vi.412273